NASDAQ:ONXX - Onyx Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Onyx Pharmaceuticals logoOnyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).

Receive ONXX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ONXX
CUSIP68339910
WebN/A
Phone+1-650-2660000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

The Truth About Cryptocurrencies

Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions

What is Onyx Pharmaceuticals' stock symbol?

Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."

What is the consensus analysts' recommendation for Onyx Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onyx Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Onyx Pharmaceuticals been receiving favorable news coverage?

News articles about ONXX stock have been trending positive on Sunday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Onyx Pharmaceuticals earned a news impact score of 0.39 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.31 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Onyx Pharmaceuticals?

Shares of ONXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Onyx Pharmaceuticals?

Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000.


MarketBeat Community Rating for Onyx Pharmaceuticals (NASDAQ ONXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ONXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.